Application prospect of low-dose porcine anti-thymocyte globulin in HLA-matched sibling donor transplantation

References

• Phan M, Chavan R, Beuttler R, et al. Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus. Clin Transl Sci. 2021;14:1303–1313.
   PubMed Web of Science ®Google Scholar
• Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119:296–307.
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialists’ Collaborative G. Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087.
   PubMed Web of Science ®Google Scholar
• Zhang H. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation. Transfus Apher Sci. 2020;59:102743.
   PubMed Web of Science ®Google Scholar
• Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:758–769.
   PubMed Web of Science ®Google Scholar
• Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.
   PubMed Web of Science ®Google Scholar
• Chang Y-J, Wu D-P, Lai Y-R, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020;38:3367–3376.
   PubMed Web of Science ®Google Scholar
• Moon JH, Sohn SK, Lambie A, et al. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant. 2014;20:556–563.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Koch C, Li L, Figueroa P, et al. Transfusion and pulmonary morbidity after cardiac surgery. Ann Thorac Surg. 2009;88:1410–1418.
   PubMed Web of Science ®Google Scholar
• Nassereddine S, Rafei H, Elbahesh E, et al. Acute Graft versus host disease: a comprehensive review. Anticancer Res. 2017;37:1547–1555.
   PubMed Web of Science ®Google Scholar
• Oran B, Champlin RE, Wang F, et al. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022;36:257–262.
   PubMed Web of Science ®Google Scholar
• Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–864.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–173.
   PubMed Web of Science ®Google Scholar
• Shin D-Y, Lee J-H, Park S, et al. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies. Bone Marrow Transplant. 2018;53:207–212.
   PubMed Web of Science ®Google Scholar
• Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
   PubMed Web of Science ®Google Scholar
• Dou L, Hou C, Ma C, et al. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hematol. 2020;99:167–179.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Rubio M-T, Bacigalupo A, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus- based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55:1093–1102.
   PubMed Web of Science ®Google Scholar
• Lv Q, Huiqin Z, Na X, et al. Treatment of severe aplastic anemia with porcine anti-human lymphocyte globulin. Curr Pharm Des. 2020;26:2661–2667.
   PubMed Web of Science ®Google Scholar
• Chen M, Liu C, Zhuang J, et al. Long-term follow-up study of porcine anti-human thymocyte immunoglobulin therapy combined with cyclosporine for severe aplastic anemia. Eur J Haematol. 2016;96:291–296.
   PubMed Web of Science ®Google Scholar
• Ma X, Wang J, Zhang W, et al. Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study. Eur J Haematol. 2016;96:260–268.
   PubMed Web of Science ®Google Scholar
• Chen X, Wei J, Huang Y, et al. Effect of antithymocyte globulin source on outcomes of HLA-matched sibling allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2018;24:86–90.
   PubMedGoogle Scholar
• Chen J, Zhang Y, Chen X, et al. Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia. Cancer Cell Int. 2022;22:89.
   PubMed Web of Science ®Google Scholar
• Wu J-L, Ma H-Y, Lu C-Y, et al. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2017 Jun;50(3):307–313.
   PubMedGoogle Scholar